House of Santen

Mental Health Study Finds Children with Vision Impairment Have Reduced Quality of Life

Retrieved on: 
Wednesday, September 13, 2023
Orbis, Well, Systematic review, Insurance, Strabismus, Depression, Anxiety, Perception, Paratriathlon, Visual impairment, Quality of life, Meta-analysis, House of Santen, Orbis International, Child, Near-sightedness, Research, Mental health, Birth control, Nursing, SWISH, Ophthalmology

NEW YORK, Sept. 13, 2023 /PRNewswire/ -- A new study by eye care nonprofit Orbis International found that children with myopia (nearsightedness) and strabismus (misalignment of the eyes) experienced significantly reduced quality of life compared to those without vision impairment. Published in the peer-reviewed journal Ophthalmology, the study also finds that surgical treatment of strabismus improves quality of life among children, underscoring the importance of early detection, treatment, and health insurance coverage of strabismus for children. Made possible with financial support from vision company Santen, the study is the first systematic review and meta-analysis of the links between quality of life in children and vision impairment, ocular morbidities, and their treatment.

Key Points: 
  • Published in the peer-reviewed journal Ophthalmology, the study also finds that surgical treatment of strabismus improves quality of life among children, underscoring the importance of early detection, treatment, and health insurance coverage of strabismus for children.
  • Made possible with financial support from vision company Santen, the study is the first systematic review and meta-analysis of the links between quality of life in children and vision impairment, ocular morbidities, and their treatment.
  • Quality of life and mental health are increasingly being recognized as important global health concerns.
  • With an estimated 70 million children experiencing vision impairment around the world, understanding the impact of these conditions on mental health is critical.

Visiox Pharma Licenses OMLONTI®

Retrieved on: 
Wednesday, July 19, 2023
Glaucoma, IOP, EP2, House of Santen, Ocular hypertension, Patient, NCE, Growth, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Disease, Pharmaceutical industry, New chemical entity

Visiox plans to launch OMLONTI in early 2024, followed by once-daily PDP-716 (brimonidine) 0.35%, positioning the company to become a leader in glaucoma, a disease with significant impact on patients.

Key Points: 
  • Visiox plans to launch OMLONTI in early 2024, followed by once-daily PDP-716 (brimonidine) 0.35%, positioning the company to become a leader in glaucoma, a disease with significant impact on patients.
  • "We believe this is a compelling transaction, as it expands our addressable market opportunity enhancing our long-term growth and profitability."
  • The strategic license provides exclusive rights in the U.S. for product manufacturing and commercialization of OMLONTI®.
  • Santen will receive an equity stake in Visiox as an upfront payment, and remains eligible to receive sales milestone payments, as well as royalties on net sales of OMLONTI® in the U.S.

Santen Agrees to Licensing Agreements and Asset Transfer for its Pharmaceutical Products in North America

Retrieved on: 
Tuesday, July 18, 2023
General Health, Pharmaceutical, Optical, Health, Inflammation, Infection, Glaucoma, IOP, Keratitis, Medication, Harrow, Research, Vernal keratoconjunctivitis, Telecanthus, Ocular hypertension, Harrow Health, Patient, Allergic conjunctivitis, Conjunctivitis, Pharmaceutical industry, House of Santen

Santen Pharmaceutical Co., Ltd. (hereafter Santen) announced today that it has signed licensing agreements and an asset transfer agreement with two U.S. companies.

Key Points: 
  • Santen Pharmaceutical Co., Ltd. (hereafter Santen) announced today that it has signed licensing agreements and an asset transfer agreement with two U.S. companies.
  • Under the terms of the agreement, Santen grants Visiox exclusive rights in the U.S. for product manufacturing and commercialization of OMLONTI®.
  • Santen is eligible to receive sales milestone payments, as well as royalties on net U.S. sales of OMLONTI®.
  • Santen will receive an upfront payment for the asset transfer and the out-licensing and is eligible for royalties on net sales of Verkazia® and Cationorm® Plus.

Santen and UBE Received FDA Approval for OMLONTI® (Omidenepag Isopropyl Ophthalmic Solution) 0.002% for the Reduction of Elevated Intraocular Pressure in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension

Retrieved on: 
Monday, September 26, 2022
Health, FDA, Other Health, Clinical Trials, Pharmaceutical, Optical, Adult, American Academy, Ocular hypertension, UBE, Health, Safety, Lens (anatomy), IOP, Risk, MD, FDA, Food, Prevalence, Glaucoma, Macular edema, Aphakia, CME, World Health Organization, Senior, Inc., Drainage, Achievement, Timolol, Severe cognitive impairment, EP2, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Eye, OTC, API, Quigley, Uncertainty, Humour, General manager, Diagnosis, Research, Optic nerve, American Academy of Ophthalmology, Drug discovery, Disease, Field line, Pharmaceutical industry, House of Santen, Ophthalmology, QD

OMLONTI was launched in Japan as Eybelis ophthalmic solution 0.002% in November 2018, and was filed for marketing approval in Asian countries in stages.

Key Points: 
  • OMLONTI was launched in Japan as Eybelis ophthalmic solution 0.002% in November 2018, and was filed for marketing approval in Asian countries in stages.
  • We are very pleased that this ophthalmic solution has been approved for glaucoma in the U.S., following approvals in Japan and Asia.
  • We have high expectations that omidenepag isopropyl will provide a new treatment option for more patients suffering from glaucoma and ocular hypertension through Santen.
  • OMLONTI (omidenepag isopropyl ophthalmic solution) 0.002%, is a relatively selective prostaglandin E2 (EP2) receptor agonist, indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

RVL Pharmaceuticals plc Reports First Quarter 2022 Financial Results; Provides Commercial Update

Retrieved on: 
Thursday, May 12, 2022
Income, Company, Research, Depreciation, U.S. Securities and Exchange Commission, Nasdaq, Patient, RVL, Tax, Nature, Marketing, Adjustment, FDA, Shape (magazine), Medication, Terminology, Sale, Optometry, GAAP, Growth, Security (finance), Annual report, GLOBE, Video game, Online gambling, Bank, Bookkeeping, EBITDA, House of Santen

BRIDGEWATER, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced financial results and business highlights for the three months ended March 31, 2022.

Key Points: 
  • Total revenues of $21.4 million, inclusive of $15.5 million in licensing revenues from Santen, compared to $0.9 million in the first quarter of 2021.
  • UPNEEQ net product sales of $5.9 million, up $5.1 million year-over-year, and up $2.8 million, or 90%, from the fourth quarter of 2021.
  • The Company reaffirms its guidance targeting net sales of UPNEEQ for the fourth quarter of 2022 of $20.0 to 25.0 million.
  • As previously announced, RVL management will host its first quarter 2022 financial results conference call as follows:

Xequel Bio, Inc. Appoints Veteran Pharmaceutical Executives to Advance Next Stage of Corporate Growth

Retrieved on: 
Wednesday, May 11, 2022
Board, Dermatology, Financial management, DNA-binding protein, Senior, NASDAQ, GLOBE, Company, Sun, Merck, Physician, Research, Â, Patient, Fibrosis, Acquisition, Inflammation, Therapy, Leadership, Ophthalmology, Tissue, Corporation, Marketing, Alcon, Ophthalmic, Inspiration, Technology, Director, Executive, Granulation tissue, Social media, General manager, Fine chemical, Management, Dermatologic and Ophthalmic Drugs Advisory Committee, Finance, House of Santen

CHARLESTON, S.C. and FORT WORTH, Texas, May 11, 2022 (GLOBE NEWSWIRE) -- Xequel Bio, Inc. (formerly FirstString Research, Inc.), a clinical stage biopharmaceutical company developing dermatologic and ophthalmic therapeutics utilizing its patented new chemical entity aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide), announced today the appointments of Jerry St. Peter as Chief Executive Officer and Wes Brazell as Chief Financial Officer.

Key Points: 
  • Both Jerry and Wes bring extensive corporate leadership, business development execution and entrepreneurial acumen to Xequel.
  • It is a pleasure to join Xequel at such a pivotal moment in its evolution, said Jerry St. Peter, Chief Executive Officer and Board Member.
  • We have also created a strong corporate identity under the Xequel Bio name, reflecting our strategic move into the Companys next chapter.
  • The Company is in the process of developing a new corporate website and updated social media accounts reflecting the Xequel Bio name.

Aerie Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 5, 2022
Pharmaceutical, Optical, Health, Other Health, U.S. Securities and Exchange Commission, Forward-looking statement, Investment, Mission statement, Table, Private Securities Litigation Reform Act, GAAP, Aerie Pharmaceuticals, EMA, IOP, Health care, NASDAQ, MHRA, DME, Nature, NDA, Software, Food, Ocular hypertension, Patient, Security (finance), Medication, Eye, Webcast, Diabetic retinopathy, FDA, Industry, Regulation of tobacco by the U.S. Food and Drug Administration, European Medicines Agency, New Drug Application, Medicines and Healthcare products Regulatory Agency, Aerie, Conjunctivitis, Glaucoma, SEC, ID, Duane syndrome, Growth, Netarsudil, Pharmaceutical industry, Bank, Risk management, House of Santen

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today reports financial results for the first quarter ended March 31, 2022 and reaffirms the business and pipeline objectives and financial guidance previously reported for 2022.

Key Points: 
  • Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today reports financial results for the first quarter ended March 31, 2022 and reaffirms the business and pipeline objectives and financial guidance previously reported for 2022.
  • During the first quarter of 2022, our net cash provided by operating activities was $61.9 million.
  • Further, an $8.0 million milestone payment was made in the first quarter of 2022 to the former shareholders of Avizorex Pharma S.L., which was acquired by Aerie in 2019.
  • Investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool.

Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Retrieved on: 
Thursday, February 24, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Medication, Income, Medicines and Healthcare products Regulatory Agency, MHRA, Glaucoma, Conjunctivitis, Webcast, European Medicines Agency, Regulation of tobacco by the U.S. Food and Drug Administration, Intellectual property, Aerie Pharmaceuticals, IOP, Investment, Security (finance), NASDAQ, ID, Duane syndrome, COVID-19, Industry, Company, Private Securities Litigation Reform Act, Nature, Table, U.S. Securities and Exchange Commission, Review, Humanitarian use licenses, Loss, New Drug Application, Aerie, Eye, Food, Software, Diabetic retinopathy, Health care, Netarsudil, FDA, EMA, Forward-looking statement, Patient, Marketing, Ocular hypertension, NDA, Mission statement, Coronavirus, GAAP, SEC, DME, Pharmaceutical industry, Animal, Bank, House of Santen

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a business update and financial guidance for 2022.

Key Points: 
  • Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a business update and financial guidance for 2022.
  • These achievements have set Aerie up for success in 2022 and beyond, said Raj Kannan, Chief Executive Officer of Aerie Pharmaceuticals.
  • For the fourth quarter 2021, our net cash used in operating activities was $30 million, bringing our full year total of net cash used to just under $100 million.
  • Aerie management will host a live conference call and webcast at 5:00 p.m. Eastern Time today to discuss Aeries financial results and provide a general business update.

Aerie Pharmaceuticals Reports Inducement Grant to Chief Executive Officer Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, December 22, 2021
General Health, Pharmaceutical, Health, Other Health, Medication, Conjunctivitis, Marketing, U.S. Securities and Exchange Commission, Retina, Patient, Private Securities Litigation Reform Act, Humanitarian use licenses, Eye, PGA, Duane syndrome, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Glaucoma, NASDAQ, Ocular hypertension, Financial compensation, Latanoprost, Industry, SEC, Intellectual property, Forward-looking statement, COVID-19, Diabetic retinopathy, Board, Ophthalmology, Netarsudil, Coronavirus, Aerie Pharmaceuticals, EMA, Company, Research, Employment, Food, Security (finance), Nature, FDA, IOP, Pharmaceutical industry, House of Santen, Aerie

In connection with his acceptance of the position of Chief Executive Officer, and in accordance with the terms of Mr. Kannans employment agreement, Mr. Kannan will receive inducement equity awards with a grant date fair value of $5.5 million in the aggregate.

Key Points: 
  • In connection with his acceptance of the position of Chief Executive Officer, and in accordance with the terms of Mr. Kannans employment agreement, Mr. Kannan will receive inducement equity awards with a grant date fair value of $5.5 million in the aggregate.
  • Aerie has two approved products, two Phase 3-ready programs, and an ongoing research program.
  • In clinical trials of Rhopressa, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage.
  • Aerie continues to focus on the research and development of additional product candidates and technologies in ophthalmology.

Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officer

Retrieved on: 
Thursday, December 16, 2021
Science, Biotechnology, Research, Pharmaceutical, Optical, Health, Infectious Diseases, Clinical Trials, Intellectual property, Ocular hypertension, Board, Aerie Pharmaceuticals, Acquisition, NASDAQ, Medication, Merck, Neurology, Eye, Organization, Forward-looking statement, FDA, Glaucoma, Acromegaly, Conjunctivitis, Diabetic retinopathy, Latanoprost, Growth, Coronavirus, EMA, Nature, U.S. Securities and Exchange Commission, Security (finance), Interview, Â, Netarsudil, COVID-19, Director, SEC, CEO, Research, Marketing, PGA, Duane syndrome, Ophthalmology, Merck Group, Food, Immunology, Company, Private Securities Litigation Reform Act, III, Industry, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, IOP, Humanitarian use licenses, Pharming, Pharmaceutical industry, House of Santen, Aerie

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today announced that Raj Kannan will join the Company as Chief Executive Officer and a director, effective December 20, 2021.

Key Points: 
  • Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today announced that Raj Kannan will join the Company as Chief Executive Officer and a director, effective December 20, 2021.
  • On behalf of the Board of Directors, I am very pleased to welcome Raj Kannan to Aerie.
  • The Aerie team has built an impressive ophthalmology company with an exciting glaucoma franchise that is global in reach and an exciting pipeline of product development candidates that has the potential to create significant value, said Raj Kannan, Chief Executive Officer.
  • Before that, Raj was Chief Commercial Officer at Kiniksa Pharmaceuticals, Ltd. (Kiniksa), where he built the commercial operations, including sales, marketing and business analytics functions.